Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops therapies for a range of oncology indications. Its lead product is GDC-0084, a small molecule inhibitor of the PI3K / AKT / mTOR pathway that is in Phase II clinical trials to treat glioblastoma multiforme. The company is also developing TRX-E-002-1 (Cantrixil), a third-generation benzopyran molecule, which is in Phase I clinical trials to treat ovarian cancer. It has collaboration agreements with The University of York, The Children's Cancer Institute Australia, The Mater Institute in Queensland, the University of Boston, and St Jude Children's Research Hospital, as well as Dana-Farber Cancer Institute. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was founded in 1994 and is based in Sydney, Australia.
Industry, Sector and Symbol
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone61 2 9472 4101
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$1.54 million
Profitability
Miscellaneous
EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable
Kazia Therapeutics (ASX:KZA) Frequently Asked Questions
What is Kazia Therapeutics' stock symbol?
Kazia Therapeutics trades on the ASX under the ticker symbol "KZA."
Has Kazia Therapeutics been receiving favorable news coverage?
Media stories about KZA stock have been trending extremely negative this week, InfoTrie Sentiment reports. The research group identifies negative and positive news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Kazia Therapeutics earned a coverage optimism score of -4.0 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View News Stories for Kazia Therapeutics.
Who are some of Kazia Therapeutics' key competitors?
Some companies that are related to Kazia Therapeutics include MediGene (MDG1), Antibe Therapeutics (ATE), Burcon NutraScience (BU), Arix Bioscience (ARIX), Verseon (VSN), 22nd Century Group (XXII), Imugene (IMU), Cynata Therapeutics (CYP), Lineage Cell Therapeutics (LCTX), BioTime (BTX), Novoheart (NVH), Medicenna Therapeutics (MDNA), Oncolytics Biotech (ONC), Sirona Biochem (SBM) and Oxford Biodynamics (OBD).
Who are Kazia Therapeutics' key executives?
Kazia Therapeutics' management team includes the folowing people:
- Dr. James Garner M.A.I.C.D., M.B.A., B.Sc., M.A., MBA, MBBS, B.Sc (, CEO, MD & Exec. Director (Age 46)
- Ms. Gabrielle Heaton, Director of Fin. & Admin.
- Ms. Catherine Jane Hill, Company Sec. (Age 60)
- Kym Robins, Director of Marketing & Communications
- Dr. Justine R. Stehn B.Sc (Hons), Ph.D., Director of ATM Program
What is Kazia Therapeutics' stock price today?
One share of KZA stock can currently be purchased for approximately A$0.63.
How big of a company is Kazia Therapeutics?
What is Kazia Therapeutics' official website?
How can I contact Kazia Therapeutics?
The company can be reached via phone at 61 2 9472 4101.
MarketBeat Community Rating for Kazia Therapeutics (ASX KZA)
MarketBeat's community ratings are surveys of what our community members think about Kazia Therapeutics and other stocks. Vote "Outperform" if you believe KZA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe KZA will underperform the S&P 500 over the long term. You may vote once every thirty days.
